Cardiology and therapy
Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy.
Daniel P Judge, Margarita Udall, Andrew M Rosen, Neil Lamarre, Elizabeth Nagelhout, Hanh Dung Dao, Mathew S Maurer
Published: 202510.1007/s40119-025-00443-3
Abstract
INTRODUCTION: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Tafamidis demonstrated efficacy in ATTR-CM clinical trials; however, real-world disease outcomes are not thoroughly characterized. We examined real-wo…
Preview only. Read the full abstract at the source